Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a unique pharmacokinetic profile (multiple elimination pathways); no dose adjustment is needed in patients with hepatic or renal impairment and it is considered to have a low potential for drug–drug interactions.

Teneligliptin has antioxidative properties and has shown endothelial protective effects in several non-clinical and clinical studies.

Teneligliptin provides a therapeutic option for a broad range of T2DM patients, including elderly subjects and those with renal impairment.